Выбор редакции
Выбор редакции
31 октября, 14:34

If Celgene Buys This Biotech, Investors Should Win Big Time

One biotech checks off all of the boxes for Celgene.

Выбор редакции
30 октября, 17:41

What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?

The third-quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players like Pfizer, Incyte and Acorda follow suit.

Выбор редакции
Выбор редакции
28 октября, 00:04

Celgene At $100: Buy, Sell, or Hold?

Shares have been devastated over the last month. Is right now a smart time to get in?

27 октября, 20:08

Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?

Agios' (AGIO) only marketed drug Idhifa that looks effective to cure patients with relapsed or refractory acute myeloid leukemia might drive the company's earnings in Q3.

27 октября, 17:13

Stock Market News For Oct 27, 2017

Markets closed mostly higher on Thursday backed by strong earnings from some prominent stocks.

Выбор редакции
Выбор редакции
Выбор редакции
26 октября, 20:02

Celgene sales target cuts signal wider biotech blues

Disappointing prospects for new medicines has exposed lack of diversification

Выбор редакции
26 октября, 19:16

Traders were blindsided by Celgene's massive earnings flop (CELG)

Celgene turned in a brutal third-quarter earnings report, missing revenue forecasts and cutting its long-term profit outlook. Traders were woefully unhedged by several measures, leaving them vulnerable to feel the brunt of the stock's 20% drop. Traders weren't prepared at all for the huge stock drop that befell Celgene after a disastrous third-quarter earnings report.

Выбор редакции
26 октября, 18:53

There's No Joy In Biotech. Mighty Celgene Just Struck Out

Celgene, missed analysts' sales projections for the third quarter by 4%, cut its guidance for 2020 by 5% to 10%. Shares are down 17%. “Our assumptions just really missed the mark, particularly in this window,” said Mark Alles, the company’s chief executive, on a conference call.

Выбор редакции
26 октября, 18:18

Celgene Corporation (CELG) Plummets After 2020 Guidance Cut

The big blow to CELG stock today came from a cut to its guidance for 2017. The company was previously expecting earnings per share to range from $7.30 to $7.35. Wall Street is looking for the company to report earnings per share of $7.31 for the year.

Выбор редакции
26 октября, 18:02

Celgene's Health Scare Is a Wake Up Call for Biotechs

Celgene shareholders got some chilling news Thursday morning, sending its shares plunging 18% when trading opened—the stock’s worst decline in more than a decade.

26 октября, 18:02

Busiest Day Of The Q3 Earnings Season

Busiest Day Of The Q3 Earnings Season

26 октября, 17:49

Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View

Celgene (CELG) beats third-quarter 2017 earnings estimates on the back of robust Revlimid performance.

26 октября, 17:31

Tall Data in Short Time

Plenty of S&P 500 companies have already reported earnings before the opening bell today, and if that's not enough, we've also got tons of economic data and newsworthy financial information to get to.

Выбор редакции
26 октября, 17:05

Why Celgene Sank to New Low Despite Q3 Earnings Beat

Despite mixed results, with earnings were fairly positive for the quarter, this was not enough to outweigh poor guidance. Shares sank to a new 52-week low.

Выбор редакции
26 октября, 16:53

Biotech Battered To 2-Month Lows As Celgene Crashes

The S&P Biotech Index is now down 9% from its early October highs, extending losses today thanks to the collapse in Celgene's share price after it lowered its outlook. As Bloomberg reports, Celgene Corp. dropped 18 percent in early U.S. trading after lowering its long-term profit target. The drugmaker, known for its hematology and oncology treatments, is under pressure to refill its pipeline as its top-selling cancer treatment faces looming competition from generics. Last week, Celgene halted a final-stage trial of an experimental Crohn’s disease drug that analysts had anticipated could become a blockbuster, raising concerns that its 2020 profit guidance might be at risk. On Thursday, the Summit, New Jersey-based company cut that long-term earnings guidance by 50 cents to $12.50 a share. Which has slammed the Biotech Index lower...   Double top anyone?